| Trial ID: | L0260 |
| Source ID: | NCT00770796
|
| Associated Drug: |
Atorvastatin
|
| Title: |
Statins for Prevention of Contrast Induced Nephropathy
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Contrast Induced Nephropathy
|
| Interventions: |
DRUG: Atorvastatin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Contrast-induced nephropathy was defined as an absolute increase of at least 0.5 mg/dl from the baseline value in serum creatinine concentration within the first 24 hours after contrast exposure and peaking up to 5 days afterwards, within 5 days after contrast exposure | Secondary: Relative increase ≥ 25% over baseline serum creatinine within 5 days after contrast agent administration, within 5 days after contrast agent administration|Adverse clinical events within 1 month, including in-hospital death and need for dialysis or hemofiltration, 1 month
|
| Sponsor/Collaborators: |
Sponsor: Ospedale Misericordia e Dolce
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
304
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2006-04
|
| Completion Date: |
2008-03
|
| Results First Posted: |
|
| Last Update Posted: |
2015-10-16
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00770796
|
